Effect of circulating plasma cell on the prognosis of patients with multiple myeloma

Li Miaoyu; Wang Lulu; Tian Biao; Xiao Wanting; Weng Yanxia; Sun Wenrui; Tang Hailong; Gao Guangxun

doi:10.13406/j.cnki.cyxb.003768

您当前的位置：

首页 >

文章列表页 >

Effect of circulating plasma cell on the prognosis of patients with multiple myeloma

Precision medicine in cancer and translational studies | 更新时间：2025-10-22

- Effect of circulating plasma cell on the prognosis of patients with multiple myeloma
- Journal of Chongqing Medical University Vol. 50, Issue 7, Pages: 905-912(2025)
- 作者机构：
  
  中国人民解放军空军军医大学第一附属医院血液内科，西安 710032
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003768
  CLC： R559
- Received：09 October 2024，
  
  Revised：2024-11-27，
  
  Accepted：08 February 2025，
  
  Published：28 July 2025
- 稿件说明：
移动端阅览
李妙雨,王露露,田彪等.循环浆细胞对多发性骨髓瘤患者预后的影响[J].重庆医科大学学报,2025,50(07):905-912.

Li Miaoyu,Wang Lulu,Tian Biao,et al.Effect of circulating plasma cell on the prognosis of patients with multiple myeloma[J].Journal of Chongqing Medical University,2025,50(07):905-912.
李妙雨,王露露,田彪等.循环浆细胞对多发性骨髓瘤患者预后的影响[J].重庆医科大学学报,2025,50(07):905-912. DOI： 10.13406/j.cnki.cyxb.003768.

Li Miaoyu,Wang Lulu,Tian Biao,et al.Effect of circulating plasma cell on the prognosis of patients with multiple myeloma[J].Journal of Chongqing Medical University,2025,50(07):905-912. DOI： 10.13406/j.cnki.cyxb.003768.

摘要

目的

探索循环浆细胞（circulating plasma cell，CPC）对多发性骨髓瘤（multiple myeloma，MM）预后的影响，结合CPC与RISS分期（Revised International Staging System），建立并验证改良的CPC-RISS分期系统。

方法

回顾性收集2006年1月至2023年6月在中国人民解放军空军军医大学第一附属医院血液科治疗的639例初治MM患者的临床数据，利用外周血涂片来计算患者CPC比例，分析CPC等相关因素对MM患者预后的影响，结合RISS分期与CPC比例建立CPC-RISS分期系统，分析不同分期患者生存及预后差异。

结果

与无CPC的患者相比，可检测的CPC与MM的诸多高危因素显著相关，存在CPC的MM患者完全缓解率更低，总生存期、无进展生存期更短。本研究使用改良CPC-RISS分期系统将MM患者分为4期，不同分期MM患者中位生存期和无进展生存期差异有统计学意义。

结论

存在CPC的MM患者表现出更具侵袭性的特征，对治疗反应较差，长期生存率降低，改良的CPC-RISS分期系统可有效预测初治MM患者预后。

Abstract

Objective

To investigate the effect of circulating plasma cell（CPC） on the prognosis of multiple myeloma（MM），and to establish and validate a modified CPC-RISS staging system based on CPC and RISS.

Methods

A retrospective analysis was performed for the clinical data of 639 treatment-naïve patients with MM who were treated in Department of Hematology，Xijing Hospital，from January 2006 to June 2023. Peripheral blood smear was used to calculate the percentage of CPC in patients，and the impact of CPC and other related factors on the prognosis of MM patients was analyzed. A CPC-RISS staging system was established based on RISS stage and the percentage of CPC，and the differences in survival and prognosis were analyzed between patients with different stages.

Results

Compared with the patients without CPC，detectable CPC was significantly associated with various high-risk factors for MM，and the MM patients with CPC had a lower complete remission rate and shorter overall survival time and progression-free survival time. The modified CPC-RISS staging system was used to classify the patients with MM into four stages，and there were significant differences in median survival time and progression-free survival time between the patients with different stages of MM.

Conclusion

The MM patients with the presence of CPC exhibit more aggressive features，worse response to treatment，and a reduction in long-term survival rate. The modified CPC-RISS staging system can effectively predict the prognosis of treatment-naïve MM patients.

关键词

Keywords

references

van de Donk NWCJ ， Pawlyn C ， Yong KL . Multiple myeloma [J ] . Lancet ， 2021 ， 397 （ 10272 ）： 410 - 427 .

Rodriguez-Otero P ， Paiva B ， San-Miguel JF . Roadmap to cure multiple myeloma [J ] . Cancer Treat Rev ， 2021 ， 100 ： 102284 .

de Larrea CF ， Kyle R ， Rosiñol L ， et al . Primary plasma cell leukemia：consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage [J ] . Blood Cancer J ， 2021 ， 11 （ 12 ）： 192 .

Jelinek T ， Bezdekova R ， Zihala D ， et al . More than 2% of circulating tumor plasma cells defines plasma cell leukemia-like multiple myeloma [J ] . J Clin Oncol ， 2023 ， 41 （ 7 ）： 1383 - 1392 .

Myeloma and Plasma Cell Disease Group of Hematologic Oncology Committee of China Anti-Cancer Association ， Multiple Myeloma Expert Committee of Chinese Society of Clinical Oncology . Chinese expert consensus on diagnosis and treatment of high risk multiple myeloma（2024） [J ] . Chin J Hematol ， 2024 ， 45 （ 5 ）： 430 - 435 .

Rajkumar SV ， Dimopoulos MA ， Palumbo A ， et al . International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma [J ] . Lancet Oncol ， 2014 ， 15 （ 12 ）： 538 - 548 .

Kumar S ， Paiva B ， Anderson KC ， et al . International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma [J ] . Lancet Oncol ， 2016 ， 17 （ 8 ）： 328 - 346 .

Professional Committee of Hematologic Oncology of China Anti-Cancer Association ， Leukemia and Lymphoma Group of Hematology Branch of Chinese Medical Association . Expert consensus on genetic testing of multiple myeloma [J ] . Chin J Med Genet ， 2019 ， 36 （ 2 ）： 99 - 102 .

Jia SS ， Bi L ， Chu YP ， et al . Development and validation of a novel prognostic model for overall survival in newly diagnosed multiple myeloma integrating tumor burden and comorbidities [J ] . Front Oncol ， 2022 ， 12 ： 805702 .

Chakraborty R ， Lentzsch S . Circulating tumor cell burden as a component of staging in multiple myeloma：ready for prime time? [J ] . J Clin Oncol ， 2022 ， 40 （ 27 ）： 3099 - 3102 .

Garcés JJ ， Cedena MT ， Puig N ， et al . Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma [J ] . J Clin Oncol ， 2022 ， 40 （ 27 ）： 3151 - 3161 .

Bertamini L ， Oliva S ， Rota-Scalabrini D ， et al . High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma [J ] . J Clin Oncol ， 2022 ， 40 （ 27 ）： 3120 - 3131 .

Jung SH ， Lee JJ . Update on primary plasma cell leukemia [J ] . Blood Res ， 2022 ， 57 （ S1 ）： 62 - 66 .

Pagano L ， Valentini CG ， de Stefano V ， et al . Primary plasma cell leukemia：a retrospective multicenter study of 73 patients [J ] . Ann Oncol ， 2011 ， 22 （ 7 ）： 1628 - 1635 .

Musto P ， Statuto T ， Valvano L ， et al . An update on biology，diagnosis and treatment of primary plasma cell leukemia [J ] . Expert Rev Hematol ， 2019 ， 12 （ 4 ）： 245 - 253 .

Kyle RA ， Maldonado JE ， Bayrd ED . Plasma cell leukemia. Report on 17 cases [J ] . Arch Intern Med ， 1974 ， 133 （ 5 ）： 813 - 818 .

Li F ， Gao YJ ， Li SS ， et al . Effect of circulating plasma cells on the prognosis of patients with multiple myeloma [J ] . Zhongguo Shi Yan Xue Ye Xue Za Zhi ， 2023 ， 31 （ 6 ）： 1771 - 1779 .

Yao WQ ， Yang HF ， You HY ， et al . The prognostic significance of circulating plasma cells in newly diagnosed multiple myeloma patients [J ] . Front Oncol ， 2023 ， 13 ： 1266868 .

Cheng QW ， Cai L ， Zhang YY ， et al . Circulating plasma cells as a biomarker to predict newly diagnosed multiple myeloma prognosis：developing nomogram prognostic models [J ] . Front Oncol ， 2021 ， 11 ： 639528 .

肖　洁，王秀菊，谢双锋，等 . 含泊马度胺全口服方案二线治疗多发性骨髓瘤的疗效与安全性分析 [J ] . 中山大学学报（医学科学版）， 2024 ， 45 （ 6 ）： 902 - 911 ．

Xiao J ， Wang XJ ， Xie SF ， et al . Efficacy and safety of total oral regimens containing pomalidomide as a second-line treatment strategy in multiple myeloma patients [J ] . J Sun Yat Sen Univ Med Sci ， 2024 ， 45 （ 6 ）： 902 - 911 ．

Liu XY ， Wu FF ， Ye W ， et al . Prognostic value of circulating plasma cells detected by flow cytometry in newly diagnosed multiple myeloma patients：a systematic review and meta-analysis [J ] . BMJ Open ， 2024 ， 14 （ 1 ）： e071548 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Prognostic study of ¹⁸F-FDG PET/CT combined with clinical characteristics in treated patients with esophageal squamous cell carcinoma

Association between albumin-corrected anion gap and prognosis in patients with acute pancreatitis: a retrospective cohort study

Role of chloride ions in the prognosis of patients with decompensated cirrhosis

Association of miR-296-5p，S-phase kinase-associated protein 2， and ribosomal protein L6 with the pathological features of prostate cancer and their influence on surgical prognosis

Related Author

Zhang Di

Pang Hua

Ren Xinyi

Cheng Gang

Qi Luyao

Xing Jixiang

Wang Guangdong

Ouyang Bingqing

Related Institution

Department of Nuclear Medicine，The First Affiliated Hospital of Chongqing Medical University

Department of Critical Care Medicine，The Seventh People’s Hospital，Shanghai University of Traditional Chinese Medicine

Graduate School，Tianjin University of Traditional Chinese Medicine

Department of Respiratory and Critical Care Medicine，The First Affiliated Hospital of Xi’an Jiaotong University

The First Clinical Medical College of Lanzhou University

⁰